SRPT logo

Sarepta Therapeutics, Inc. (SRPT) EBITDA

Annual EBITDA:

$316.89M+$770.58M(+169.85%)
December 31, 2024

Summary

  • As of today, SRPT annual EBITDA is $316.89 million, with the most recent change of +$770.58 million (+169.85%) on December 31, 2024.
  • During the last 3 years, SRPT annual EBITDA has risen by +$634.29 million (+199.84%).
  • SRPT annual EBITDA is now at all-time high.

Performance

SRPT EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSRPTincome statement metrics

Quarterly EBITDA:

-$41.06M-$171.50M(-131.48%)
September 30, 2025

Summary

  • As of today, SRPT quarterly EBITDA is -$41.06 million, with the most recent change of -$171.50 million (-131.48%) on September 30, 2025.
  • Over the past year, SRPT quarterly EBITDA has dropped by -$77.39 million (-213.03%).
  • SRPT quarterly EBITDA is now -123.33% below its all-time high of $176.01 million, reached on December 31, 2024.

Performance

SRPT Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSRPTincome statement metrics

TTM EBITDA:

-$21.08M-$77.39M(-137.44%)
September 30, 2025

Summary

  • As of today, SRPT TTM EBITDA is -$21.08 million, with the most recent change of -$77.39 million (-137.44%) on September 30, 2025.
  • Over the past year, SRPT TTM EBITDA has dropped by -$156.89 million (-115.52%).
  • SRPT TTM EBITDA is now -107.75% below its all-time high of $271.97 million, reached on December 31, 2024.

Performance

SRPT TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSRPTincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

SRPT EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+169.8%-213.0%-115.5%
3Y3 Years+199.8%+64.9%+95.7%
5Y5 Years+148.1%+67.7%+96.3%

SRPT EBITDA Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Yearat high+153.3%-123.3%+85.7%-107.8%+96.0%
5Y5-Yearat high+148.1%-123.3%+85.7%-107.8%+96.3%
All-TimeAll-Timeat high+148.1%-123.3%+85.7%-107.8%+96.3%

SRPT EBITDA History

DateAnnualQuarterlyTTM
Sep 2025
-
-$41.06M(-131.5%)
-$21.08M(-137.4%)
Jun 2025
-
$130.44M(+145.5%)
$56.31M(+190.7%)
Mar 2025
-
-$286.47M(-262.8%)
-$62.10M(-122.8%)
Dec 2024
$316.89M(+169.8%)
$176.01M(+384.5%)
$271.97M(+100.3%)
Sep 2024
-
$36.33M(+202.0%)
$135.81M(+45.4%)
Jun 2024
-
$12.03M(-74.7%)
$93.40M(+347.3%)
Mar 2024
-
$47.60M(+19.4%)
-$37.77M(+81.9%)
Dec 2023
-$453.69M(+23.7%)
$39.86M(+754.6%)
-$208.93M(+38.8%)
Sep 2023
-
-$6.09M(+94.9%)
-$341.51M(+24.5%)
Jun 2023
-
-$119.13M(+3.6%)
-$452.41M(+15.1%)
Mar 2023
-
-$123.56M(-33.3%)
-$532.66M(-10.6%)
Dec 2022
-$594.85M(-87.4%)
-$92.73M(+20.7%)
-$481.60M(+0.6%)
Sep 2022
-
-$116.98M(+41.3%)
-$484.54M(-25.1%)
Jun 2022
-
-$199.38M(-175.0%)
-$387.43M(-12.8%)
Mar 2022
-
-$72.51M(+24.2%)
-$343.37M(+14.5%)
Dec 2021
-$317.41M(+31.9%)
-$95.67M(-381.4%)
-$401.58M(+13.7%)
Sep 2021
-
-$19.87M(+87.2%)
-$465.16M(+18.7%)
Jun 2021
-
-$155.32M(-18.8%)
-$572.38M(-4.9%)
Mar 2021
-
-$130.72M(+17.9%)
-$545.70M(-4.1%)
Dec 2020
-$466.21M(+29.2%)
-$159.25M(-25.3%)
-$524.32M(+9.1%)
Sep 2020
-
-$127.09M(+1.2%)
-$576.89M(-2.1%)
Jun 2020
-
-$128.64M(-17.6%)
-$565.11M(-6.4%)
Mar 2020
-
-$109.34M(+48.4%)
-$530.90M(-8.0%)
Dec 2019
-$658.71M(-108.0%)
-$211.81M(-83.7%)
-$491.58M(-19.4%)
Sep 2019
-
-$115.31M(-22.1%)
-$411.80M(-13.4%)
Jun 2019
-
-$94.43M(-34.9%)
-$362.99M(+2.2%)
Mar 2019
-
-$70.02M(+47.0%)
-$371.33M(-12.6%)
Dec 2018
-$316.66M(-811.6%)
-$132.04M(-98.5%)
-$329.81M(-50.9%)
Sep 2018
-
-$66.51M(+35.3%)
-$218.54M(-28.7%)
Jun 2018
-
-$102.78M(-260.8%)
-$169.79M(-41.6%)
Mar 2018
-
-$28.49M(-37.1%)
-$119.92M(+6.9%)
Dec 2017
-$34.73M(+86.6%)
-$20.78M(-17.1%)
-$128.80M(+33.9%)
Sep 2017
-
-$17.75M(+66.5%)
-$194.76M(+15.8%)
Jun 2017
-
-$52.91M(-41.6%)
-$231.21M(+3.0%)
Mar 2017
-
-$37.37M(+56.9%)
-$238.30M(+7.9%)
Dec 2016
-$259.76M(-21.7%)
-$86.73M(-60.0%)
-$258.70M(-10.1%)
Sep 2016
-
-$54.20M(+9.7%)
-$235.05M(-1.6%)
Jun 2016
-
-$60.00M(-3.9%)
-$231.31M(-9.0%)
Mar 2016
-
-$57.77M(+8.4%)
-$212.13M(-3.1%)
Dec 2015
-$213.42M(-64.0%)
-$63.09M(-25.0%)
-$205.65M(-10.5%)
Sep 2015
-
-$50.45M(-23.6%)
-$186.13M(-10.6%)
Jun 2015
-
-$40.82M(+20.4%)
-$168.30M(-7.3%)
Mar 2015
-
-$51.30M(-17.7%)
-$156.80M(-21.1%)
Dec 2014
-$130.10M(-46.2%)
-$43.56M(-33.5%)
-$129.50M(-9.4%)
Sep 2014
-
-$32.63M(-11.3%)
-$118.41M(-7.3%)
Jun 2014
-
-$29.31M(-22.1%)
-$110.37M(-12.8%)
Mar 2014
-
-$24.00M(+26.1%)
-$97.89M(-10.7%)
Dec 2013
-$89.01M(-215.9%)
-$32.47M(-32.0%)
-$88.39M(-34.2%)
Sep 2013
-
-$24.59M(-46.1%)
-$65.85M(-37.8%)
Jun 2013
-
-$16.83M(-16.0%)
-$47.79M(-32.2%)
Mar 2013
-
-$14.50M(-46.0%)
-$36.16M(-28.3%)
Dec 2012
-$28.18M(+18.6%)
-$9.93M(-52.1%)
-$28.18M(-10.2%)
Sep 2012
-
-$6.53M(-25.7%)
-$25.56M(+14.9%)
Jun 2012
-
-$5.20M(+20.3%)
-$30.03M(+13.5%)
Mar 2012
-
-$6.52M(+10.9%)
-$34.71M(-3.7%)
Dec 2011
-$34.63M
-$7.32M(+33.5%)
-$33.48M(-21.8%)
Sep 2011
-
-$11.00M(-11.4%)
-$27.49M(-40.7%)
Jun 2011
-
-$9.87M(-86.6%)
-$19.53M(-37.8%)
DateAnnualQuarterlyTTM
Mar 2011
-
-$5.29M(-299.4%)
-$14.18M(+12.9%)
Dec 2010
-$19.47M(-37.8%)
-$1.32M(+56.4%)
-$16.27M(+12.5%)
Sep 2010
-
-$3.04M(+32.6%)
-$18.60M(-2.6%)
Jun 2010
-
-$4.52M(+38.9%)
-$18.13M(+1.1%)
Mar 2010
-
-$7.39M(-102.1%)
-$18.32M(-29.7%)
Dec 2009
-$14.13M(+12.1%)
-$3.65M(-42.4%)
-$14.13M(-9.2%)
Sep 2009
-
-$2.57M(+45.5%)
-$12.94M(+13.2%)
Jun 2009
-
-$4.71M(-47.2%)
-$14.91M(-1.2%)
Mar 2009
-
-$3.20M(-29.6%)
-$14.73M(+1.9%)
Dec 2008
-$16.07M(+48.3%)
-$2.47M(+45.5%)
-$15.01M(+15.2%)
Sep 2008
-
-$4.53M(-0.0%)
-$17.71M(+16.3%)
Jun 2008
-
-$4.53M(-30.1%)
-$21.15M(+15.3%)
Mar 2008
-
-$3.48M(+32.5%)
-$24.97M(+21.1%)
Dec 2007
-$31.09M(-0.7%)
-$5.16M(+35.3%)
-$31.63M(+8.9%)
Sep 2007
-
-$7.97M(+4.5%)
-$34.71M(-3.7%)
Jun 2007
-
-$8.35M(+17.7%)
-$33.49M(-4.5%)
Mar 2007
-
-$10.14M(-23.0%)
-$32.04M(-3.7%)
Dec 2006
-$30.89M(-99.1%)
-$8.24M(-22.1%)
-$30.89M(-14.3%)
Sep 2006
-
-$6.75M(+2.3%)
-$27.03M(-24.5%)
Jun 2006
-
-$6.91M(+23.2%)
-$21.70M(-11.6%)
Mar 2006
-
-$8.99M(-105.6%)
-$19.45M(-25.3%)
Dec 2005
-$15.52M(+33.0%)
-$4.38M(-206.9%)
-$15.52M(+0.3%)
Sep 2005
-
-$1.43M(+69.4%)
-$15.56M(+17.1%)
Jun 2005
-
-$4.66M(+8.0%)
-$18.78M(+10.1%)
Mar 2005
-
-$5.06M(-14.6%)
-$20.89M(+9.8%)
Dec 2004
-$23.16M(-33.2%)
-$4.42M(+4.9%)
-$23.16M(+9.0%)
Sep 2004
-
-$4.65M(+31.3%)
-$25.44M(-1.3%)
Jun 2004
-
-$6.77M(+7.6%)
-$25.12M(-16.5%)
Mar 2004
-
-$7.32M(-9.3%)
-$21.57M(-24.0%)
Dec 2003
-$17.39M(+27.6%)
-$6.70M(-54.8%)
-$17.39M(-20.3%)
Sep 2003
-
-$4.33M(-34.9%)
-$14.46M(+4.6%)
Jun 2003
-
-$3.21M(-1.9%)
-$15.15M(+22.4%)
Mar 2003
-
-$3.15M(+16.6%)
-$19.53M(+18.7%)
Dec 2002
-$24.01M(-61.7%)
-$3.77M(+24.9%)
-$24.01M(+2.4%)
Sep 2002
-
-$5.02M(+33.8%)
-$24.60M(-7.9%)
Jun 2002
-
-$7.58M(+0.6%)
-$22.81M(-20.7%)
Mar 2002
-
-$7.63M(-74.7%)
-$18.90M(-28.4%)
Dec 2001
-$14.85M(-51.1%)
-$4.37M(-35.3%)
-$14.72M(-11.7%)
Sep 2001
-
-$3.23M(+12.2%)
-$13.18M(-5.8%)
Jun 2001
-
-$3.68M(-6.6%)
-$12.45M(-8.2%)
Mar 2001
-
-$3.45M(-22.0%)
-$11.51M(-24.7%)
Dec 2000
-$9.82M(-22.8%)
-$2.83M(-12.8%)
-$9.23M(-46.2%)
Sep 2000
-
-$2.50M(+8.4%)
-$6.32M(-5.7%)
Jun 2000
-
-$2.73M(-134.1%)
-$5.97M(-14.6%)
Mar 2000
-
-$1.17M(-1391.9%)
-$5.21M(+10.0%)
Dec 1999
-$8.00M(-5.3%)
$90.40K(+104.2%)
-$5.79M(+0.4%)
Sep 1999
-
-$2.16M(-9.5%)
-$5.82M(-5.5%)
Jun 1999
-
-$1.97M(-13.0%)
-$5.51M(-4.2%)
Mar 1999
-
-$1.75M(-2745.8%)
-$5.29M(-4.1%)
Dec 1998
-$7.60M(-123.5%)
$66.00K(+103.5%)
-$5.09M(+14.5%)
Sep 1998
-
-$1.86M(-6.2%)
-$5.95M(-19.2%)
Jun 1998
-
-$1.75M(-13.9%)
-$4.99M(-17.8%)
Mar 1998
-
-$1.54M(-92.4%)
-$4.24M(-32.5%)
Dec 1997
-$3.40M(-100.0%)
-$800.00K(+11.1%)
-$3.20M(-33.3%)
Sep 1997
-
-$900.00K(+10.0%)
-$2.40M(-60.0%)
Jun 1997
-
-$1.00M(-100.0%)
-$1.50M(-200.0%)
Mar 1997
-
-$500.00K
-$500.00K
Dec 1996
-$1.70M
-
-

FAQ

  • What is Sarepta Therapeutics, Inc. annual EBITDA?
  • What is the all-time high annual EBITDA for Sarepta Therapeutics, Inc.?
  • What is Sarepta Therapeutics, Inc. annual EBITDA year-on-year change?
  • What is Sarepta Therapeutics, Inc. quarterly EBITDA?
  • What is the all-time high quarterly EBITDA for Sarepta Therapeutics, Inc.?
  • What is Sarepta Therapeutics, Inc. quarterly EBITDA year-on-year change?
  • What is Sarepta Therapeutics, Inc. TTM EBITDA?
  • What is the all-time high TTM EBITDA for Sarepta Therapeutics, Inc.?
  • What is Sarepta Therapeutics, Inc. TTM EBITDA year-on-year change?

What is Sarepta Therapeutics, Inc. annual EBITDA?

The current annual EBITDA of SRPT is $316.89M

What is the all-time high annual EBITDA for Sarepta Therapeutics, Inc.?

Sarepta Therapeutics, Inc. all-time high annual EBITDA is $316.89M

What is Sarepta Therapeutics, Inc. annual EBITDA year-on-year change?

Over the past year, SRPT annual EBITDA has changed by +$770.58M (+169.85%)

What is Sarepta Therapeutics, Inc. quarterly EBITDA?

The current quarterly EBITDA of SRPT is -$41.06M

What is the all-time high quarterly EBITDA for Sarepta Therapeutics, Inc.?

Sarepta Therapeutics, Inc. all-time high quarterly EBITDA is $176.01M

What is Sarepta Therapeutics, Inc. quarterly EBITDA year-on-year change?

Over the past year, SRPT quarterly EBITDA has changed by -$77.39M (-213.03%)

What is Sarepta Therapeutics, Inc. TTM EBITDA?

The current TTM EBITDA of SRPT is -$21.08M

What is the all-time high TTM EBITDA for Sarepta Therapeutics, Inc.?

Sarepta Therapeutics, Inc. all-time high TTM EBITDA is $271.97M

What is Sarepta Therapeutics, Inc. TTM EBITDA year-on-year change?

Over the past year, SRPT TTM EBITDA has changed by -$156.89M (-115.52%)
On this page